contraindications for glp 1 agonists to π°οΈ60-second review: Mnemonics and Updates in GLP -1 in Glucagon-like peptide-1 receptor agonists in
Description
Kulak-Bejda A et al

The companys Phase III product Rybelsus, already FDA approved for cardiovascular risk factors and type 2 diabetes, is being positioned for a label expansion to include obesity
Supervision: Fahad S

Clinically, the results of the injectable and oral formulations are comparable, with the main difference being how the medication enters the bloodstream

So far, Novo is furthest ahead in developing an obesity pill

We don't yet understand how these drugs truly work What's the mechanism for the benefits of GLP-1 in the heart, liver or brain
